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ABSTRACT 
 
 
Predictive ability of NGAL as a marker of renal damage: evaluation 
of multiple clinical settings 
 
 
 Introduction. Neutrophil Gelatinase-Associated Lipocalin (NGAL) 
belongs to the family of lipocalins and it is produced by several cell types, 
including renal tubular epithelium. 
In the kidney its production increases during acute damage and this is reflected 
by the increase in serum and urine levels. In animal studies and clinical trials, 
NGAL was found to be a sensitive and specific indicator of acute kidney injury 
(AKI). 
 Purpose. The aim of this work was to investigate, in a prospective 
manner, whether urine NGAL can be used as a marker in preeclampsia, kidney 
transplantation, VLBI and diabetic nephropathy. 
 Materials and methods. The study involved 44 consecutive patients 
who received renal transplantation; 18 women affected by preeclampsia (PE); a 
total of 55 infants weighing ≤1500 g and 80 patients with Type 1 diabetes. 
 Results. A positive correlation was found between urinary NGAL and 
24 hours proteinuria within the PE group. The detection of higher uNGAL 
values in case of severe PE, even in absence of statistical significance, confirms 
that these women suffer from an initial renal damage. In our population of 
VLBW infants, we found a positive correlation of uNGAL values at birth with 
differences in sCreat and eGFR values from birth to day 21, but no correlation 
was found between uNGAL values at birth and sCreat and eGFR at day 7. 
systolic an diastolic blood pressure decreased with increasing levels of uNGAL. 
The patients with uNGAL <25 ng/ml had significantly higher levels of systolic 
blood pressure compared with the patients with uNGAL >50 ng/ml ( p<0.005). 
Our results indicate the ability of NGAL to predict the delay in functional 
recovery of the graft. 
 4 
           Conclusions. In acute renal pathology, urinary NGAL confirms to be a 
valuable predictive marker of the progress and status of acute injury. 
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1.      INTRODUCTION 
 
 
Neutrophil Gelatinase-Associated Lipocalin (NGAL, also known as 
lipocalin-2, siderocalin, 24p3, or LCN2) is a small molecule belonging to a 
well-defined superfamily of proteins called lipocalins. Human NGAL consists 
of a single disulphide-bridged polypeptide chain of 178 amino-acid residues; it 
is released from neutrophil granules as a 25 kDa monomer, a 46 kDa disulfide-
linked homodimer, and a disulfide- linked heterodimer with gelatinase B 
(Matrix Metalloproteinase 9) [Uttenthal et al. 2005]. 
NGAL was initially found in activated neutrophils. However, many 
other cells, including kidney tubular cells, have been proven to produce NGAL 
in response to various insults. Different levels of NGAL gene expression has 
been demonstrated in several human tissues, such as uterus, prostate, salivary 
glands, lung, trachea, stomach, colon and kidney [Cowland et al. 1997]. 
As Dr. Roland Strong, one of the main researchers on these proteins, 
stated, “Lipocalins are small proteins that cells send out to bind things and 
carry them back” [Goetz et al. 2000]. This family includes many proteins, such 
as α1-microglobulin, retinol-binding protein 4, prostaglandin D synthase, and 
nitrophorines, which are specialized in binding and transporting small 
hydrophobic molecules (Table 1). 
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Table 1.  Principal members of Lipocalin Protein Superfamily. 
 
Lipocalins are involved in several processes: retinol transport, 
invertebrate cryptic coloration, olfaction, pheromone transport, and 
prostaglandin synthesis. Despite limited sequence similarity, the lipocalin fold 
is remarkably well conserved.  
The core structure consists of an eight-stranded, antiparallel, 
continuously hydrogen-bonded β-barrel which defines a calyx-or cup-shaped 
structure with an enclosed ligand binding site. The loops linking the strands 
are typically short β-hairpins, except the first loop, describing a large Ω loop 
that usually folds back onto the barrel, partially constricting the binding site. 
There is a short helix at the N-terminus and an α-helix at the C-terminus 
(Figure 1) [Flower et al. 1996]. 
 
 
 
 
 
 
 
 
 
Figure 1. NGAL structure. 
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Unlike other lipocalins, NGAL shows no affinity for retinoic acid 
(REA), but is reported to bind the tripeptide N-formyl-Met-Leu-Phe, a potent 
neutrophil chemoattractant, and possibly other lipophilic mediators of 
inflammation such as PAF, leukotriene B4 and LPS. Through these 
interactions, NGAL is proposed in important immunomodulatory functions. 
The role of NGAL in tissue remodeling and tumorigenesis is still unknown.  
 
1.1     PHYSIOLOGY OF NGAL 
 
Role in iron metabolism 
 
The delivery of iron to cells is critical for cell growth and development. 
Iron is located at the active site of a large numbers of proteins including 
regulators of intermediary metabolism and DNA synthesis, and it stabilizes 
three-dimensional protein structure [Cooper et al. 1997; Nyholm et al. 1993]. 
In addition, iron is a unique regulator of gene expression, activating 
both transcriptional [Yamaguchi et al. 1996] and posttranscriptional 
mechanisms [Rouault et al. 1997]. For these reasons, the acquisition of iron is 
central to cell survival, growth and maturation, and its metabolism is tightly 
regulated by many proteins. Most cells acquire iron by capturing iron-located 
transferrin. After binding to receptors, transferrin enters an endocytic pathways 
[van Renswoude et al. 1982]. 
Within endosomes, iron dissociates from transferrin and is transferred 
across the vesicle membrane into the cell cytoplasm. In epithelia, this pathway 
is uniquely located in the basal domain of the cell. However, despite its 
ubiquity and quantitative importance in adult physiology, the transferrin 
pathway is not essential for the delivery of iron to many tissues, including 
epithelia. Hypotransferrinemic mice
hpx/hpx 
[Huggenvik et al. 1989; Trenor et al. 
2000] and atransferrinemic humans [Hamill et al. 1991] have severe defects in 
hematopoiesis and central nervous system development, but most epithelial 
organs are normal.  
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Likewise, mice lacking the transferrin receptor-1 initiate organogenesis 
but succumb to the effect of anemia. Given that iron is necessary for all cells, 
there must be other pathways for iron acquisition in non-hematopoietic cells. 
These additional pathways might involve the local expression of iron-
trafficking proteins, such as lactoferrin, putative low molecular weight 
siderophores, and cell surface iron transporters like DMT-1 (Divalent Metal 
Transporter-1) [Ward et al. 1999]. 
Siderophores are proteins produced by bacteria to scavenge iron from 
the extracellular space. They trap iron with high affinity and ensure continuous 
supply of iron necessary for survival and growth of bacteria. Enterochelin is 
one such siderophore produced by some strains of bacteria. The evidence for 
role of NGAL in iron metabolism came from crystallographic studies. 
To test the hypothesis that NGAL directly interferes with siderophore-
mediated iron uptake by bacteria, Goetz et al. investigated the effect of 
exogenous NGAL on the growth of bacteria under iron-limiting conditions. 
They noticed that XL1-Blue E.coli expressing NGAL fail to grow in M9 
minimal media unless supplemented with 10 μM iron. However, the addiction 
of exogenous apo-NGAL, at concentration of only 5 μM, resulted in a dramatic 
20-fold inhibition of growth. Adding iron just sufficient to saturate the NGAL 
present rescues growth, demonstrating that NGAL doesn’t have any 
antibacterial property beyond iron sequestration [Goetz et al. 2002]. 
Neutrophil gelatinase-associated lipocalin interacts with cells by 
specific cell-surface receptors. Hitherto, two receptors have been identified: the 
megalin-cubilin multiscavenger complex found on the brush-border surface of 
renal tubular epithelial cells [Hvidberg et al. 2005] and the 24p3R (NGAL was 
originally called 24p3), an organic cation transporter. 
NGAL has also been proposed to interact with some other receptors 
such as extracellular protein kinases, hepatocyte growth factor, and gelatinase 
B. These receptors seem to have a role in cellular trafficking and endocytosis 
of NGAL. Endocytosis occurs as NGAL protein alone (apo-NGAL) or NGAL 
complexed with iron-binding siderophores (Holo-NGAL). 
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The cellular effects depend on the form of NGAL endocytosed. When 
transported as apo-NGAL, it captures intracellular iron and transports it outside 
leading to depletion of intracellular iron. On the other side, when endocytosed 
as Holo-NGAL, it releases iron-siderophore complex and contributes to 
intracellular iron pool. The depletion of iron cellular pools, under particular 
condition, may even lead to apoptosis (Figure 2) [Devireddy et al. 2005]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic of neutrophil gelatinase-assocaited lipocalin (NGAL) cellular  
turnover. 
 
 
Role in innate immunity to bacteria  
 
Goetz et al. showed that the most important ligands of lipocalins are 
siderophores [Goetz et al. 2000; Goetz et al. 2002], small non-peptidic iron-
containing molecules produced in bacteria, plants, and mammals that, through 
iron transport and supply, involved in cellular growth and survival. 
Immunohistochemistry revelaed massive staining for NGAL protein in 
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epithelial cells in both diverticulitis, appendicitis, ulcerative colitis and Crohn's 
disease, as well as in neoplastic conditions [Nielsen et al. 1996]. 
All these conditions are characterized by significant inflammation and 
in some cases also by neutrophil infiltration, but the latter does not explain the 
presence of NGAL in epithelial cells, and in situ hybridation has demonstrated 
a marked upregulation of NGAL mRNA in the epithelial cells in the 
aforementioned situations.  
Strong and coll. reported that recombinant NGAL generated by E. coli 
was deeply red in color in contrast to recombinant NGAL generated by insect 
cells. It was shown that this red color was due to an iron molecule that was 
trapped in the siderophore of E. coli, enterochelin, indicating that NGAL is a 
siderophore binding protein [Strong et al. 1998]. 
The binding of enterochelin by NGAL is strong (dissociation constant 
0.4 nM), and the siderophores are significantly more stable when bound in the 
lipocalin pocket of NGAL. This means that the ability of NGAL to sequester 
iron via siderophores is durable.  
This evidence was confirmed by experiments where apo-NGAL, NGAL 
generated without siderophore, was added to E. coli. NGAL was able to 
completely block growth of E. coli under iron poor condition but NGAL with 
siderophore iron was not. Besides enterochelin, NGAL has been shown to bind 
to other siderophores including carboxymycobactin, a soluble protein secreted 
by mycobacteria. This massive induction of NGAL in epithelial cells made us 
suspect that NGAL serves a role in innate immunity. 
NGAL inhibitory role on bacterial growth by sequestering siderophore 
iron was investigated in a knock-out mouse model generated by Flow et al. 
They showed that the resistance of wild-type mice was indeed due to their 
ability to induce NGAL synthesis and reduce the amount of siderophore iron 
available to bacteria, since providing the wildtype mice with siderophore iron 
from a source which NGAL cannot bind, made the mice as vulnerable to 
infection as knock-out mice [Flo et al. 2004]. This study indicated that NGAL 
works as a bacteriostatic agent by sequestering siderophore bound iron, but 
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NGAL is not bactericidal, and prevents bacterial growth only as long as NGAL 
is able to sequester siderophores. This authors concluded that NGAL 
participates in the antibacterial iron depletion strategy of the innate immune 
system. 
NGAL is released by neutrophils at sites of infection and inflammation 
to sequester bacterial ferric siderophores thus participating in the antibacterial 
iron-depletion strategy of the innate immune system. However, while other 
components of this system, such as lactoferrin, simply bind to and sequester 
free iron, NGAL is specific for iron already earmarked for bacterial use as 
ferric siderophore complexes. NGAL bind siderophores and prevents its uptake 
by microorganism (Figure 3) [Borregaard et al. 2006]. 
     
 
 
 
 
 
 
 
 
Figure 3. Epithelial cells synthetize and release NGAL in response to inflammation. 
Microorganism synthetize and release siderophores that capture iron and provide a 
mechanism for supplying this essential nutrient to the bacteria. NGAL binds 
siderophores and prevent their uptake in microorganism and thus deprive them of this 
essential nutrient. 
 
 
Role in kidney development 
 
NGAL was originally purified as a protein that promotes the 
mesenchymal to ephitelial conversion of ureteric bud cell lines. This effect 
could potentially be related to the ability of NGAL to donate iron to the cells. It 
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has been suggested that NGAL is involved in kidney development [Gwira et 
al. 2005]. 
Gwira et al. showed that some growth factors such as hepatocyte growth 
factor (HGF) are able to stimulate epithelial cells to express NGAL which 
participates in mesenchymal-epithelial transformation via its capability to 
augment cellular iron uptake. 
At concentrations below those found to mediate iron transport, purified 
NGAL can induce a promigratory and probranching effect that is dependent on 
ERK activation. The suppression of NGAL expression using short hairpin 
RNA produces increased cyst formation by tubular cells. 
However, the simultaneous addiction of NGAL and HGF leads to direct 
association of the two proteins, and results in a partial inhibition of HGF-
mediated activation of c-Met and the downstream MAPK and 
phosphatidylinositol 3-Kinase signaling pathways. This inhibitory effect 
downregulates HGF-stimulated single cell migration, and limits branching 
morphogenesis at both the single cell and multicellular level. These 
experiments demonstrate that the local expression of NGAL plays a regulatory 
role in epithelial morphogenesis by promoting the organisation of cells into 
tubular structures while simultaneous negatively modulating the branching 
effects of HGF.  
Yang et al. demonstred that, administering purified NGAL to early 
epithelial progenitor cells obtained from a specific peripheral niche of murine 
metanephric mesenchyme, a clear proliferative effect was observed, followed 
by epithelial differentiation of these elements with the subsequent generation 
of nephron-shape formations expressing glomerular, proximal, and distal 
tubular surface cellular markers. However, this mechanism does not seem to be 
essential for in vivo embryo kidney development because genetic model of 
NGAL inactivation do not give rise to a blockade of renal maturation or 
complete agenesis of this organ, probably because of the presence of other 
more redundant pathways. At present, the exact molecular mechanism through 
which NGAL exert its growth effect on renal cells has not yet been clarified. A 
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fundamental role seems to be played by the association between NGAL and 
iron-binding siderophores and its subsequent interaction with specific surface 
receptors (24p3R; megalin).  
Conversely, NGAL alone (apo-NGAL), as well as NGAL associated 
with an iron-free or gallium-binding siderophore, appears to have a 
proapoptotic effect very similar to that on which the antibacterial properties of 
this protein depend, as a result of depletion of intracellular iron reserves [Yang 
et al. 2002]. 
Considered together, these observations confirm the importance of iron 
capture for the development of embryonic kidneys, but also suggest the 
presence of an alternative iron-delivery pathway, distinct from the main 
systems currently recognized in mammals (which is mediated by transferrin). 
However, it cannot be excluded that other mechanisms, for instance the 
activation of extracellular kinases or binding with matrix metalloproteinase 9, 
may be involved in determining growth/differentiation properties of NGAL 
[Bolignano et al. 2008]. 
 
1.2     NGAL AS A BIOMARKER  
 
NGAL has been proven to be a promising biomarker in a variety of 
other renal and non-renal conditions, as shown in Table 2. NGAL is a useful 
clinical biomarker for early diagnosis, for predicting disease severity, for 
therapeutic monitoring, and for predicting clinical outcomes. The following 
section discusses the potential role of NGAL in different renal and systemic 
diseases.  
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Table 2. Potential use of NGAL as a biomarker. 
 
Acute kidney injury 
 
Acute kidney injury (AKI) formerly named acute renal failure (ARF) of 
any origin is associated with a high mortality in the critically ill patient, despite 
significant technical advances in therapeutics including renal replacement 
therapy (RRT) such as dialysis [Brar et al. 2008]. 
AKI is defined as the abrupt (e.g. within 48 hours) and sustained 
decrease in renal function resulting in retention of nitrogenous (urea and 
creatinine) and non-nitrogenous waste products as well as in dysregulation of 
cellular volume and electrolyte handling. In clinical practice, the diagnosis of 
AKI relies on a decreased glomerular filtration rate (GFR), increased serum 
creatinine with or without oliguria, classified in RIFLE (Risk, Injury, Failure, 
Loss, and End-stage kidney disease) [Bellomo et al. 2004b] and AKIN (Acute 
Kidney Injury Network) criteria [Mehta et al. 2007]. 
The classification for AKI is defined by three stages of increasing 
severity, which correspond to the RIFLE criteria for risk (stage 1), injury (stage 
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2), and failure (stage 3). Loss and end-stage kidney disease were removed and 
redefined as outcomes.  
However, there are major limitations to the use of creatinine for 
estimating GFR. Serum creatinine does not accurately reflect GFR during the 
non-steady state of AKI by probably overestimating GFR. Thus, minor 
changes of creatinine, as typically seen earlier in AKI, do already reflect 
substantial declines in GFR [Bellomo et al. 2004a]. To overcome these 
obstacles, an extensive search for more suitable laboratory markers monitoring 
impaired renal function is required.  
NGAL appears to be the most promising molecule among the many 
novel molecules [Ronco et al. 2008]. 
Misha et al. first proposed NGAL as a new early biomarker. In mouse 
model of ischemia-reperfusion injury (IRI) subjected to 30 minutes of bilateral 
renal artery occlusion, NGAL was found to be one of the seven genes which 
were highly upregulated. NGAL was easily detected in the urine within 2 hours 
following ischemia. In the same study, separate sets of mice were subjected to 
5, 10, and 20 minutes of ischemia. Urinary NGAL was detected even in these 
mice, appearing after 6 hours in mice with 5 minutes of ischemia and after 4 
hours in mice with 10 and 20 minutes of ischemia. Thus, NGAL was found to 
be a very sensitive marker of ischemic AKI and its levels correlated to the dose 
and duration of renal ischemia [Mishra et al. 2003]. 
Additionally, the same authors reported that uNGAL was detectable 
after 1 day of cisplatin administration in a mouse model of nephrotoxic AKI, 
suggesting its sensitivity in other models of tubular injury [Mishra et al. 2008]. 
NGAL has been widely investigated across a range of different clinical settings 
of AKI. 
However, with accumulating evidence, conflicting observations raised 
some concerns about the robustness of NGAL as a biomarker. Haase et al. 
performed a meta-analisys of data from 19 studies including 2500 patients 
from observational studies to estimate the diagnostic and prognostic accuracy 
of NGAL and its value in AKI. The population included both adults and 
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children, studied in several clinical conditions: most frequently investigated 
AKI after cardiac surgery, followed by AKI in critically ill patients and after 
exposure to contrast media for coronary angiography. 
In conclusion, NGAL was found to be a useful early predictor of AKI, 
with urine or plasma/serum NGAL levels functioning as well. NGAL levels 
also revealed a prognostic value for clinical endpoints, such as the initiation of 
dialysis and mortality. Unfortunately, substantial extrarenal NGAL generation 
in response to systemic stress can increase urinary NGAL excretion in the 
absence of AKI as well, and this may also arise from chronic and not just 
acute, renal disease [Haase et al. 2009]. 
 
 
Renal transplantation 
 
Kidney allograft function after transplantation varies from a rapid 
increase in GFR, causing brisk reductions in serum creatinine to primary 
allograft failure. 
Delayed graft function (DGF) is defined as the need for dialysis within 
1 week of transplantation, and occurs in 20% to 33% of deceased donor kidney 
transplant (DDKTs) [Halloran et al. 2001; Mikhalski et al 2008].Recent 
strategies for increasing the donor pool include using “extended-criteria donor” 
(ECD) and “donation after cardiac death “ (DCD) kidneys. The deleterious 
effects of DGF in the immediate post-transplant period include increased 
lengths of stay and total hospital costs, mainly due to the need for dialysis 
[Rosenthal et al. 1991]. 
Hall et al. examined the long-term role that DGF plays in patient and 
graft survival in a recent meta-analysis and demonstrated more than 40% 
increased risk of graft loss at 1 year with DGF [Yarlagadda et al. 2008]. Even 
in patients not dialyzed after transplant, some studies have shown poorer long-
term outcomes with “slow graft function”(SGF) compared with “immediate 
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graft function” (IGF) [Rodrigo et al. 2004; Humar et al. 2002; Johnston et al. 
2006]. 
Hall et al. carried out a multicenter, prospective cohort study of patients 
receiving DDKTs to evaluate the timing and efficacy of using urinary NGAL 
for predicting recovery of graft function and the need for dialysis within 1 
week after transplantation. The study revealed that urinary NGAL is an early, 
non-invasive, and accurate predictor of the need for dialysis within the first 
week of kidney transplantation. 
After transplantation, local NGAL production within DGF kidneys 
contributes to the high circulating level, reflecting the ischemia-reperfusion 
stress applied to the transplanted kidney before organ withdrawal, during the 
storage period or during reperfusion. In DGF kidneys, in situ expression of 
NGAL by the tubular epithelium has been demonstrated by a proteomic study 
performed 1 hour after arterial clamp release. This suggested that the high 
plasma NGAL value in DGF patients throughout the study period may partly 
be related to transplanted kidney production [Hall et al. 2010]. 
Compared with previous studies that assessed plasma NGAL as an early 
and sensitive marker of the onset of AKI with normal baseline kidney function, 
it is relevant to consider renal transplantation as a specific model. Starting with 
a high plasma level, fast plasma NGAL level decrease appeared to be a very 
sensitive marker of renal function, suggesting less post-ischemic tissue 
damage. This decline may be initiated by less renal transplant NGAL 
production or a negative cumulative marker balance related to extra-renal 
production decrease, renal washout of the marker and modification of renal 
uptake.  
NGAL is physiologically filtered by the glomerulus and almost 
reabsorbed within the proximal tubule. After ischemia-reperfusion aggression 
in transplanted kidneys, tubular reabsorption may still be impaired despite 
glomerular filtration rate restoration and early graft function (EGF). 
Since urine output is strictly compensated by intravenous saline infusion 
during the first postoperative day, there was a wide distribution of urine output 
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values among patients. Because the proportion of patient with urine output less 
than 1 L at day 1 is significantly higher in DGF patient than in EGF, still 13% 
of the patients with immediate graft function had a urine output less than 1 L at 
day 1. As in the present study, it appears that immediate urine output is not a 
useful tool to discriminate EGF from DGF patients [Bataille et al. 2011]. 
Biomarker validation could be included as an integral part of ongoing 
intervention trials for DGF. Although animal studies have suggested effective 
therapies in IRI, human trials of DGF to date have been less promising, likely 
because of late detection [Perico et al. 2004]. 
If biomarker levels in the immediate post-transplant period can be 
shown to accurately predict duration of injury and longer term graft function, 
they could be very useful as surrogate markers. Ultimately, insight into this 
area of research may provide support for the early detection and stratification 
of IRI, which will facilitate future DGF/AKI intervention trials [Parikh et al. 
2008].  
 
Chronic kidney disease 
 
Recent studies aimed at defining whether NGAL may have a role in 
renal and systemic adaptions to chronic kidney disease. The principal 
hypothesis was that chronic renal damage could influence the physiological 
balance of this protein in a way similar to that observed for acute injury 
conditions.  
 
Polycystic kidney disease. NGAL has been shown to be an excellent 
indicator of severity of CDK in patients affected by autosomal dominant 
polycystic kidney disease, in which uNGAL and sNGAL levels correlated well 
with resisual renal function, serum creatinine, and cyst enlargement in patients 
with autosomal dominant polycystic kidney disease [Bolignano et al. 2007]. 
Wei et al. showed that addition of NGAL to the cells from PKD1 mutant mice 
suppressed the cyst development [Wei et al. 2008]. 
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Glomerular disease. Brunner et al. observed a cohort of 35 cases of 
childhood-onset systemic lupus erythematosus (SLE) and found a strong 
correlation of uNGAL levels with renal disease activity. In addition, uNGAL 
levels correlated with the activity and chronicity score on renal histology 
[Brunner et al. 2006]. In a similar study, Suzuki et al. found strong correlation 
of uNGAL levels with SLE disease activity. However, plasma NGAL levels 
did not show such correlation in this study [Suzuki et al. 2008].Ding et al. 
evaluated a cohort of patients affected by immunoglobulin A nephropathy. 
They compared levels of uNGAL, urinary N-acetyl-β-D-glucosaminidase 
(uNAG) and urinary creatinine with 40 healthy controls. uNGAL levels were 
significantly elevated in IgA nephropathy patients compared with healthy 
controls [Ding et al. 2007].  
Bolignano et al. recently reported that patients with proteinuria 
associated with idiophatic glomerulonephritis had also increased uNGAL 
levels in comparison with healthy subject, and these values correlated well 
with GFR and serum creatinine level, as well as daily proteinuria extent 
[Bolignano et al. 2008]. 
 
Other systemic conditions. Poniatowski et al. found serum and urine 
NGAL as sensitive early markers of renal impairment in patients with chronic 
heart failure [Poniatowski et al. 2009]. 
In another study, uNGAL levels were found to be significantly elevated 
in patients with chronic heart failure. Its level correlated directly with urine 
albumin excretion rate and inversely with estimated glomerular filtration. So, 
uNGAL is a potential biomarker for the cardio-renal syndrome [Damman et al. 
2008]. 
La Manna et al. evaluated the ability of serum and urinary NGAL to 
predict renal function in the first weeks of life of preterm infants. From 
September 2008 to July 2009, infants weighing ≤1500g at birth with no major 
congenital anomalies or sepsis were eligible. They proved that uNGAL levels 
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at birth may have a predictive role in very LBW (VLBW) infants [La Manna et 
al. 2011]. 
Smith et al. indicated that uNGAL, along with other urine 
metalloproteinases, as a satisfactory biomarker for the presence of brain tumor 
[Smith et al. 2008].Urinary NGAL can also potentially serve as a marker to 
assess the severity of inflammatory bowel diseases. Fernandez et al. found 
uNGAL-MMP9 complex as a useful biomarker for breast cancer.  
In addition to NGAL, many other molecules have been studied and 
found useful as early biomarkers of AKI when compared with serum 
creatinine. Performance of NGAL has been comparable or better than other 
molecules [Fernandez et al. 2005]. 
Preeclampsia is a leading cause of maternal and fetal/neonatal mortality 
and morbidity worldwide. The early identification of patients with an increased 
risk for preeclampsia is therefore one of the most important goals in obstetrics. 
The availability of effective biomarkers would allow not only the detection of 
patients at risk but also a correct early disease assessment in asymptomatic 
pregnant women, a timely intervention and closer surveillance.  
Among the potential biomarkers, NGAL has been evaluated through 
normal pregnancy and pregnancies complicated by preeclampsia syndrome, 
because of the previous evidences proving its reliability as a marker of renal 
damage. Considering that the kidney damage is always present in preeclampsic 
women, NGAL has recently gained interest as a candidate diagnostic 
biomarker in early diagnosis of this disease. A recent study demonstrated 
significant increased serum NGAL levels in preeclampsic women compared to 
the control women and a direct correlation to blood pressure and proteinuria, 
showing a high sensitivity (75%) and specificity (94.5%) [D’Anna et al. 2008]. 
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1.3    NGAL IN PATIENT WITH DIABETIC NEPHROPATHY 
 
           NGAL has been proven to be a very promising marker in diabetes. 
Diabetic nephropathy is a severe complication that develops in 30-40% of 
diabetic patients [Parving et al. 2008]. Additionally, diabetic nephropathy is 
associated with a higher risk of other micro and macrovascular complications, 
including cardiovascular disease, neuropathy and retinopathy, and with an 
increased all-cause mortality. To prevent the development of diabetic 
nephropathy, early screening for albuminuria and early renoprotective 
interventions are essential.  
Albumin excretion is primarily a result of glomerular damage, but lack 
of tubular reabsorption of albumin also contributes to albuminuria. Thus, the 
urinary albumin excretion is mainly a product of glomerular but also tubular 
damage and, as the damage to these sites is not always correlated, a more 
specific marker of tubular injury is needed.  
It has been repeatedly demonstrated that glomerular and 
tubulointerstitial injury are both important factors in the pathophysiology of 
diabetic nephropathy [Gilbert et al. 1999]. In this regard, Nielsen et al. reported 
that levels of the tubular marker urinary liver type fatty acid-binding protein, 
are increased in Type 1 diabetic patients, even before they develop signs of 
glomerular damage, i.e. albuminuria. Thus it has been hypothesized that 
NGAL could complement albuminuria (the established marker of glomerular 
injury) for the early detection of diabetic nephropathy. These authors observed 
higher urinary NGAL accompanied by rising levels of albuminuria; moreover 
the urinary/plasma NGAL ratio was significantly increased in diabetic patients 
compared with healthy subjects and also increased along with the degree of 
albuminuria. No significant differences were found in this ratio between the 
microalbuminuric group and the normoalbuminuric group [Nielsen et al. 2009; 
Nielsen et al. 2010].  
It has also been hypothesized that diabetes, as a hyperglycaemic and 
proinflammatoric state, induces increased NGAL production in extra-renal 
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tissues, a hypothesis which has been supported by a study in type 2 diabetic 
patients. The increase of urinary NGAL might represent a protective strategy 
against renal damage, an hypothesis that has been primarily explored in acute 
kidney injury.  
Bolignano et al. suggested that NGAL may play an important role in the 
pathophysiology of renal adaptation to diabetes, probably as a defense 
mechanism to mitigate tubular suffering. In this study, patients with type 2 
diabetes mellitus divided into three groups: normoalbuminuria, 
microalbuminuria and diabetic nephropathy. All the diabetic patients showed 
increased NGAL values compared with healthy subjects; higher NGAL levels 
were found in the diabetic patients without early signs of glomerular damage 
(normoalbuminuric). Both urinary NGAL and serum NGAL rose in parallel with 
the severity of renal disease, reaching the highest levels in patients with diabetic 
nephropathy. Therefore NGAL measurement might constitute a valuable and 
noninvasive tool for the evaluation of renal involvement in diabetic patients as 
well as for the early diagnosis of incipient nephropathy [Bolignano et al. 2009]. 
 
1.4     SNPs 
 
In recent years the scientific community has given increasing attention 
to genetic factors potentially related to individual susceptibility of patients to 
the development of various multifactorial diseases. 
The predisposition to suffer from certain diseases, or the type of 
response to a given treatment may depend on the presence of polymorphisms 
(Single Nucleotide Polimorphisms, SNPs), or small variations in the genome. 
The polymorphisms are not the direct cause of the disease, but their presence 
can influence (increasing or reducing) the risk [Misefari et al. 2001]. 
SNPs are DNA sequence variations, due to an alteration of a single 
nucleotide (A, T, C or G) in the sequence of genome, which can occur either in 
a coding region (exons), or in a non-coding region (introns, regulatory 
sequences) of the gene.  
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SNPs sited in a coding sequence do not necessarily change the 
aminoacid sequence of the protein, due to degeneracy of the genetic code. A 
SNP which produces the same polypeptide sequence is called a synonymous 
polymorphism (or silent mutation). If a different polypeptide sequence is 
produced the polymorphism is a replacement polymorphism, either missense, 
which results in a different aminoacid, or nonsense, which results in a 
premature stop codon. 
SNPs that are not in protein-coding regions may still affect gene 
splicing, transcription factor binding, messenger RNA degradation, or the 
sequence of non-coding RNA. Gene expression affected by this type of SNP is 
referred to as an expression SNP and may be located upstream or downstream 
from the gene. 
The nucleotide polymorphisms seem to fulfill the characteristics of an 
ideal genetic marker: abundant in the genome (in fact represent 90% of all 
human genetic variation), readily reproducible in different laboratories, and 
easy to locate. SNPs, in general, can be very useful for genetic studies of 
population and to detect traces of selection: they are indeed very common in 
populations and on a case by case basis give rise to small effects on the 
phenotype of an individual. It is well established that specific SNPs or groups 
of SNPs defined by a haplotype result influence the individual susceptibility or 
resistance to many of the most common human diseases, namely diabetes, 
cancer, cardiovascular disease, Alzheimer's disease, arthritis. 
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2.      PURPOSE 
 
 
 
 
 
 
The primary goal of this study was to assess the effectiveness of NGAL 
as a predictive marker of disease onset and/or disease progression in 
pathological acute and chronic kidney disease (primary endpoint). 
We evaluated its efficacy in different clinical conditions: 
 
 Very low birth infant (VLBI) 
 Preeclampsia 
 Kidney transplantation 
 Diabetic nephropathy 
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3.      MATERIALS AND METHODS 
 
3.1     PATIENTS 
 
Very low birth weight (VLBW) infants 
A total of 55 infants weighing ≤1500 g hospitalized in S. Orsola 
University Hospital Neonatal Intensive Care Unit from September 2008 to July 
2009 were eligible for the study. Exclusion criteria were major congenital 
anomalies, abnormal karyotype, sepsis at birth (C-reactive protein > 1.5 mg/dL 
or positive microbiological blood culture). Forty-four neonates (80%) showed 
increased eGFR during the first 3 weeks of life (normal renal function, NRF 
group), while 11 infants (20%) demonstrated stable or progressively 
deteriorating renal function (impaired renal function, IRF group). 
Demographic characteristics, clinical parameters and biomarkers values 
of the infants are reported in Table 3.  
 
Table 3. Demographic characteristics and clinical parameters of infants. Results are 
expressed as mean ± SD, unless otherwise stated. RDS, respiratory distress syndrome.   
 
 
All infants 
(n=40) 
IRF 
group 
(n=8) 
NRF 
group  
(n=32) 
p 
Male, n (%) 18 (40%) 3 (37.5%) 13 
(40.6%) 
1 
BW, g  956.8 ± 
305.9 
989.4±271 826.3± 0.1 
GA, weeks  27±2 28.0±2.3 26.5±3.7 0.06 
Intrauterine growth retardation, n (%) 8 (20%) 1 (12.5%) 7 
(21.9%) 
1 
PDA, n (%) 26 (65%) 3 (37.5%) 23 
(71.9%) 
0.1 
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Mechanical ventilation and/or surfactant 
for RDS, n (%) 
27 (67.5%) 5 (62.5%) 22 
(68.7%) 
0.29 
Ibuprofen treatment for PDA n (%) 14 (35%) 3 (37.5%) 11 
(34.4%) 
1 
Aminoglycosides, n (%) 31 (77.5%) 6 (75%) 25 
(78.1%) 
1 
Dopamine and/or dobutamine, n (%) 13 (32.5%) 6 (75%) 7 
(21.9%) 
0.0085 
Hypotension at birth, n (%) 2 (5%) 1 (12.5%) 1 (3.1%) 0.36 
 
 
Preeclampsia 
One-year prospective case-control study was performed at the 
Department of Obstetrics and Prenatal Medicine of the University of Bologna.  
Eighteen women affected by preeclampsia (PE) and 22 women with 
uncomplicated pregnancy matched for gestational age were enrolled. Mild PE 
was defined as the development of hypertension (systolic blood pressure ≥ 140 
mmHg or diastolic blood pressure ≥ 90 mmHg on two occasions at least six 
hours apart) and proteinuria (> 0.3 g/day) after 20 weeks of gestation. Severe 
PE was diagnosed on the basis of the presence of one or more of the following 
evaluation criteria: severe hypertension (systolic blood pressure ≥ 160 mmHg 
or diastolic blood pressure ≥ 110 mmHg on two occasions at least six hours 
apart during bed rest), or severe proteinuria (≥ 5 g in a 24-hour urine specimen 
or 3 + or greater in two random urine specimens collected at least 4 hours 
apart). 
 Atypical PE was recognized as the presence of gestational hypertension 
or proteinuria associated with signs and/or symptoms of organ damage. 
Demographic and clinical characteristics of study population are 
reported in Table 4.  
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Table 4. Demographic and clinical characteristics of study population. 
 PE 
(n = 18) 
Controls 
(n = 22) 
p-value 
Maternal age (years)* 37±3.9 37±4.3 Ns 
Nulliparity ** 50 50 Ns 
Multiple pregnancies** 16% 9% Ns 
Preconceptional BMI* 26.5±7.5 23.6±4.4 Ns 
Smokers** 5.6 4.6 Ns 
Trhombophlia** 5.6 4.6 Ns 
Nephropathy** 5.6 0 0.05 
Chronic hypertension** 16.7 0 0.0001 
 
             *: media +/- SD  **: percentage 
 
 
Kidney transplantation 
Forty-four consecutive patients who received renal transplantation at the 
Unit of Nephrology, Dialysis and Transplantation of the S. Orsola University 
Hospital were enrolled between February 2009 and May 2010.  
Urine samples were collected before transplantation (T0) and at 1, 3, 7, 
14 and 30 days after transplantation (T1, T2, T3, T4, and T5 respectively).  
Demographic and clinical characteristics of the patients, and 
transplantation-related variables are reported in Table5.  
 
Table 5. Recipients clinical and demographic characteristics. Continuous variables 
are presented as means ± standard deviation, and categorical variables are presented 
as n (%). 
 
Age (years) 53.9 ± 9.6 
Sex (M; F) 29; 15 (65.9%; 34.1%) 
Time on dialysis prior to transplantation (months)   63.9 ± 29.3 
Dialysis modality (hemodialysis; peritoneal dialysis) 37; 7 (84.1%; 15.9%) 
Delayed graft function (DGF) 17 (38.6%) 
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Early graft function (EGF) 26 (59.1%) 
Primary not function 1 (2.3%) 
 
 
Diabetic nephropathy 
The population consisted of 80 patients with Type 1 diabetes recruited 
from the Diabetes and Pediatrics Clinic of the S. Orsola University Hospital. 
Based on urinary NGAL levels the patients were divided into three 
groups: 49 with urinary NGAL < 25 ng/ml; 15 with urinary  NGAL between 25 
and 50 ng/ml; and 16 with urinary NGAL> 50 ng/ml. 
The main clinical characteristic and biochemical parameters of the 
patients are presented in Table 6. 
 
Table6. Clinical characteristic and biochemical parameters in the three groups of 
diabetic patients. 
 uNGAL 
 < 25 ng/ml 25.1-50 ng/ml > 50 ng/ml 
n 49 15 16 
Gender (male/female) 36/13  10/5  4/12  
Age (yr) 47 47 43 
Systolic blood pressure M1 (mmHg) 126 127 118 
Systolic blood pressure M10 (mmHg) 126 124 124 
Diastolic blood pressure M1 (mmHg) 78 78 73 
Diastolic blood pressure M10 (mmHg) 79 76 76 
HbA1c M1(%) 8 8 8 
HbA1c M10 (%) 8 8 8 
Creatinine M1 (mg/dl) 2 1 1 
Creatinine M10 (mg/dl) 1 1 1 
Microalbuminuria M1 (mg/24h) 18 11 23 
Microalbuminuria M10 (mg/24h) 29 16 13 
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3.2     URINE COLLECTION 
 
Very low birth weight (VLBW) infants 
Urine specimens were collected 24 to 48 hours after birth. A blood 
specimen was also collected after 7 days and 3 weeks from birth for the 
determination of serum creatinine (sCreat) and the estimation of eGFR. Blood 
samples were collected in Vacutainer tubes with clot activator and gel for 
serum separation. Serum was separated by centrifugation at 2500 rpm for 15 
min, and sCreat was assayed immediately.  
All urine samples were collected with a urine bag for 3 hours, and 
urinary creatinine (uCreat) was assayed immediately. For the determination of 
uNGAL, urine samples were centrifuged for 10 min at 1500 rpm within 24 
hours of collection and the supernatant was stored at -20°C until analysis. 
 
Preeclampsia 
Urine collection were performed at time of PE diagnosis. Specimens 
were kept refrigerated at 4°C until they were sent to laboratory, then they were 
stored within 4 hours of collection and analyzed later. Urine samples were 
centrifuged at 1500 rpm for 10 minutes, and the supernatants were frozen at -
20°C until analysis.  
The levels of urinary NGAL was measured using a commercially 
available ELISA test (BioPorto Diagnostics, Gentafte, Denmark). 
 
Kidney transplantation 
Urine samples were collected before transplantation (T0) and at 1, 3, 7, 
14 and 30 days after transplantation (T1, T2, T3, T4, and T5 respectively). 
  Urine samples were centrifuged at 1500 rpm for 10 minutes and the 
supernatant was frozen at -20°C until analysis. 
 The levels of urinary NGAL was measured using a commercially 
available ELISA test (BioPorto Diagnostics, Gentafte, Denmark). 
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Diabetic nephropathy 
Urine specimens were collected at two times: M1 and M10. Urine 
samples were centrifuged at 1500 rpm for 10 minutes and the supernatant was 
frozen at -20°C until analysis. 
Urine NGAL measurements obtained by ARCHITECT® assay. 
 
 
3.3   ELISA TEST ( Enzyme Linked Immunosorbent Assay ) 
 
All the samples were analyzed in the laboratory of our Unit. Urinary levels of 
NGAL were assayed using commercially available ELISA tests (NGAL 
ELISA Kit 036; BIOPORTO Diagnostic, Grusbakken, Denmark). ELISA 
(Enzyme Linked Immunosorbent Assay) consists of a solid-phase enzyme 
immunoassay to detect the presence of an analyte in a liquid sample, i.e. 
serum, plasma, urine or cell culture medium.  
NGAL ELISA is an assay performed in microwells coated with a 
monoclonal antibody against human NGAL. Bound NGAL is detected with a 
horseradish peroxidise (HRP)-conjugated monoclonal antibody and the assay is 
developed by incubation with a color-forming substrate. At first, aliquots of 
calibrators, diluted samples and any controls were incubated with HRP-
conjugated detection antibody in the coated microwells. Only NGAL binds to 
both coat and detection antibody, while unbound materials are removed by 
washing. In the second step, a chromogenic peroxidase substrate containing 
tetramethylbenzidine (TMB) was added to each test well. The HRP linked to 
the bound detection antibody reacts with the substrate to generate a colored 
product. The enzymatic reaction was stopped chemically, and the color 
intensity was read immediately with a reader DV 990 microplate BV5UV 
(GVD, Rome, Italy) by measuring absorbance at 450 nm (Figure 4).  
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Figure 4. Enzyme Linked Immunosorbent Assay. 
 
The color intensity (absorbance) is a function of the concentration of 
NGAL originally added to each well. The results for the calibrators are used to 
construct a calibration curve from which the concentrations of NGAL in the test 
specimens are calculated and expressed in pg/ml. The sensitivity limit was 4 
pg/ml. 
 
3.4     ARCHITECT NGAL assay 
 
The ARCHITECT NGAL assay utilizes a non-competitive, sandwich 
format with chemiluminescent signal detection. The assay includes a 
microparticle reagent prepared by covalently attaching an anti-NGAL antibody 
to paramagnetic particles and a conjugate reagent prepared by labeling a second 
anti-NGAL antibody with acridinium. The mouse anti-NGAL antibodies were 
developed at Abbott Laboratories and are directed against distinct, non-
overlapping NGAL epitopes. The calibrators are prepared with recombinant 
human NGAL expressed and purified at Abbott Laboratories. The recombinant 
NGAL is a full length protein. 
The assay employs an automated sequence consisting of an 18 min 
incubation step with sample (2.5 μL) and microparticle reagent (50 μL), a solid 
phase wash step, and a 4 min incubation step with conjugate reagent (50 μL). 
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Following the immunochemistry steps, the solid phase is washed again and the 
acridinium label is triggered with peroxide and base to generate the signal. The 
assay calibrators are at 0, 10, 100, 500, 1000 and 1500 ng/mL and the 
concentration of NGAL measured is proportional to the signal. 
 
3.5    MOLECULAR BIOLOGY  
 
Extraction of genomic DNA  
The patients' genomic DNA was isolated using GenomicPrep ™ Blood 
DNA Isolation Kit (Amersham Biosciences, Piscataway, NJ, USA). The kit is 
designed to isolate DNA from nucleated blood cells.  
Red blood cells, which lack genomic DNA, were lysed using 900 μl of 
lysis solution (RBC) which were added to 300 μl of whole blood. The mix was 
agitated by inversion and incubated at room temperature for 10 minutes. After 
centrifugation at 13000-16000 g for one minute, the supernatant was removed, 
leaving the pellet leaving behind the visible white cell pellet and 10–20 μl of 
residual liquid.  
Remaining white cells were then lysed in the presence of a DNA 
preservative using 300 μl of an anionic detergent which solubilizes the cellular 
components. The DNA preservative limits the activity of DNases that are 
present in the cells and elsewhere in the environment. Contaminating RNA was 
removed by treatment with with 1.5 μl of RNase precipitation solution (at 37°C 
for 15 minutes). Any cytoplasmic and nuclear proteins are removed by salt 
precipitation adding 100 μl of precipitation solution 
After centrifugation at 13,000–16,000 x g for 3 minutes, the proteins 
formed a tight, dark brown pellet, well separated from the supernatant; this 
fraction, containing the DNA, was collected in another tube. Genomic DNA is 
isolated by precipitation with the addition of 300 μl of isopropyl alcohol at 
100%. After two consecutive washes with 300 l of 70% ethanol, the pellet is 
left to dry for 10-15 minutes. Subsequently, the dried sample is rehydrated with 
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100 l of sterile distilled water (DNase RNase free H2O Ultra Pure, Invitrogen 
Life Technologies, Carlsbad, USA) overnight at room temperature.  
 
Agarose gel electrophoresis 
 Electrophoresis is a procedure which enables the sorting of molecules 
based on size and charge, using an electric field that allows molecules to 
migrate toward the pole that has the opposite charge [Westermeier R. et al. 
1997]. In biology there are many molecules bearing ionizable groups (such as 
aminoacids, proteins and nucleic acids) and then, at each pH value, are present 
in solution as electrically charged species. For example, due to the presence of 
phosphate groups (PO4
3-
), the negatively charged DNA molecules migrate 
toward the positive pole (anode) when subjected to an electric field.  
Agarose gel electrophoresis can be used for the separation of DNA 
fragments ranging from 50 base pair to several megabases. The distance 
between DNA bands of a given length is determined by the percent agarose in 
the gel. The agarose is a linear polysaccharide, normally used at concentrations 
of 1% and 3%.  
Agarose gels are obtained by suspending dry powdered agarose in an 
aqueous buffer, such as TBE (Tris Borate EDTA), then boiling the mixture 
until the agarose melts into a clear solution. The solution is then poured onto a 
gel-tray and allowed to cool to room temperature to form a rigid gel. Upon 
hardening, the agarose forms a matrix whose density is determined by the 
initial agarose concentration.  
The pore size is a function of agarose concentration: large pores are 
obtained using low concentrations, while smaller pores are obtained with higher 
concentrations. Depending on the concentration of agarose (and thus pore size), 
it is possible to resolve a wide size-range of DNA fragments, usually ranging 
between 100 kb and 20 kb. In the preparation of the agarose gel ethidium 
bromide is added to a final concentration of approximately 0.5 mg/ml. The 
ethidium bromide is one of the most widely used dyes for the detection of 
nucleic acids: it is a planar aromatic organic molecule capable of intercalation 
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between the nucleobases and emits orange light at 590 nm when excited by UV 
radiation with length wave between 254 and 306 nm. DNA bands on the 
segments of interest are displayed using a BIO-RAD Gel Doc 1000. 
In this study, agarose gel electrophoresis was used for different 
purposes:  
- Quantitative estimate of genomic DNA. Genomic DNA isolated from 
patient’s blood was visualised on agarose gel 1 % in TBE 1X. One l of 
DNA extract with 4 μl of sterile distilled, and 5 μl of 2X loading buffer 
(red cresol 1 mg / ml, glycerol 625 mg / ml) were loaded in each well.  
DNA molecular weight markers VI and VIII (Roche Applied Science, 
Mannheim, Germany) were used to quantify genomic DNA. 
- Assessment of PCR results. Five l of PCR product were analyzed 
directly by 1.5% agarose gel electrophoresis followed by ultraviolet 
detection the presence and the yield of the expected bands. DNA 
molecular weight markers VI and VIII (Roche Applied Science) served 
for size determination and confirmation of the bands. 
- Analysis of the results of RFLP (Restriction Fragment Length 
Polymorphism). The PCR products digested with restriction enzymes 
were loaded on 2.5% agarose gel at (+ equal volume of 2X loading 
buffer). The recognition of the bands according to sizes obtained from 
digestion was carried out using DNA molecular weight markers VI and 
VIII (Roche Applied Science).  
-  
Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) is a technique in molecular 
biology to amplify a single or a few copies of a piece of DNA across several 
orders of magnitude, generating thousands to millions of copies of a particular 
DNA sequence. PCR was developed in 1983 by Kary Mullis who was awarded 
the Nobel Prize in Chemistry ten years later for his work on PCR.  
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PCR amplification can be performed in vitro very rapidly, providing the 
amount of genetic material necessary for subsequent applications.  
The method relies on thermal cycling, consisting of cycles of repeated 
heating and cooling of the reaction for DNA melting and enzymatic replication 
of the DNA.  
Almost all PCR applications employ a heat-stable DNA polymerase, 
such as Taq polymerase, an enzyme originally isolated from the bacterium 
Thermus aquaticus. This DNA polymerase enzymatically assembles a new 
DNA strand from DNA building-blocks, the nucleotides, by using single-
stranded DNA as a template and primers, which are required for initiation of 
DNA synthesis. Primers are DNA oligonucleotides containing sequences 
complementary to the target region. As PCR proceeds, the DNA generated is 
itself used as a template for replication, initiating a chain reaction in which the 
DNA template is exponentially amplified. 
The sequence to be amplified can be synthesized from a discrete 
molecule or from a larger molecule. In both cases, the reaction product will be a 
discrete molecule of dsDNA ends corresponding to the 5' oligomers used. A 
basic PCR set up requires several components and reagents which include: 
- DNA template that contains the DNA region (target) to be amplified.  
- A pair of primers that hybridize to sequences flanking the target. Each 
primer is usually composed of a number of nucleotides ranging from 20 
to 30; 
- Taq polymerase or another DNA polymerase with a temperature 
optimum at around 70°C.  
- Deoxynucleoside triphosphates (dNTPs; nucleotides containing 
triphosphate groups). 
- Buffer solution, providing a suitable chemical environment for optimum 
activity and stability of the DNA polymerase.  
- MgCl2, a cofactor of DNA polymerase. 
- Monovalent cation potassium ions.  
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- In some cases dimethyl sulfoxide (DMSO), to facilitate the separation 
between two DNA strands, improving the efficiency of PCR. 
 
The reaction involves a series of successive steps of denaturation, 
annealing and extension that are repeated for a large number of cycles (Figure 
5).  
 
Figure 5. Schematic drawing of the PCR cycle. 
 
The selected segment of DNA is separated into single strands by heating 
(denaturation) and then is cooled, allowing the two oligonucleotides serving as 
primers to hybridize with their complementary sequences on both strands 
(annealing). In the following phase, the DNA polymerase (Taq polymerase), 
sets in motion the elongation of the primer by adding nucleotides to the 3' end 
(extension). 
During the first and every subsequent reaction cycle, the extension of 
each oligonucleotide on the original strand produces a new ssDNA molecule of 
indefinite length. The long products originated in this way serve as template for 
the complementary primer during subsequent cycles, and their extension by 
Taq polymerase molecules makes PCR products of a defined length, 
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corresponding to that of the target region. Hence a chain reaction proceeds 
leading to the accumulation of a specific dsDNA (amplicon) in exponentially 
manner with the number of cycles of reaction. The PCR amplification however 
is characterized by a plateau effect, in which, beyond a certain number of 
cycles (25 to 30), the amount of PCR product does not increase exponentially, 
but it is saturated. The plateau effect is due to several causes: 
− the competition between the products of previous cycles and the primers 
for the hybridization; 
− the molar ratio of the concentrations of DNA-polymerase and DNA 
template, which is reduced up to a critical value; 
− the accumulation of pyrophosphates that inhibit the polymerase; 
− the progressive decrease in the concentration of one or more components 
necessary for the reaction; 
− the specificity of the sequence to be amplified and the initial value of its 
concentration. 
 
Restriction Fragment Length Polymorphism (RFLP) 
The RFLP technique is based on the ability of enzymes of bacterial 
origin, called "restriction enzymes", to recognize a specific DNA sequence and 
cut the phosphodiester bond between two specific nucleotides. Restriction 
enzymes are divided into two great classes: (1) exonuclease, which catalyze the 
hydrolysis of single nucleotides present in 5' or 3' and begin to cut in a 
continuing process towards the opposite end, and (2) endonuclease that instead 
cut the phosphodiester bonds of both strands in a linear or circular DNA 
molecule.  
All endonucleases recognize specific motives in DNA sequence 
(restriction site) with variable sizes of 4, 6, 8 or more base pairs. Restriction 
enzymes belong to the system of restriction and modification (RM) that 
includes endonucleases and methylases. This system has been observed in 
microorganisms and is used to eliminate foreign DNA from other species. The 
enzymes that are part of the MR system can be classified into 3 types (I, II, III) 
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based on the subunit composition, the need for cofactors, and the mode of 
action (Pinguod A. et al. 1995). 
In type I and III restriction enzymes, both the methylase and restriction 
activity of the enzyme is carried out by one large enzyme complex; thee 
enzymes recognize specific sequences in the duplex DNA but cut the DNA far 
away from the recognition sites. 
In contrast type II enzymes cut DNA at a specific and precise site; they 
are the most widely used for DNA manipulation. 
Type II enzymes are homodimers which recognize the palindromic 
sequence of 4-8 bp and, in the presence of Mg
2+, 
cut the double helix of DNA 
(Pinguod A. et al. 1995). 
Most type II restriction enzymes recognize symmetric sequences, 
whereas a small minority recognize somewhat non-symmetric sequences, 
resulting in blunt ends or sticky ends in the 5 'or 3'. The enzyme that runs on the 
nucleotide sequence and stops when it recognizes the restriction site. 
The recognition of the site allows a conformational change that activates 
the catalytic center allowing the cutting of the phosphodiester bond and 
consequently the enzyme is detached and available for another restriction 
enzyme reaction. 
A polymorphism of restriction (Restriction Fragment Length 
Polymorphism, RFLP) is defined as a SNP located in a short DNA sequence 
that is recognized and subsequently cleaved by a specific restriction enzyme. 
The change of one base within the restriction site sequence prevents recognition 
by the enzyme that, therefore, fails to cut the nucleotide sequence. The enzyme 
must be chosen so that the recognition site is recognized and cut only if it 
contains a certain sequence. The identification of alleles can be done by 
electrophoretic separation on agarose gel according to the size of the fragments 
produced following by restriction enzyme digestion. 
The method consists of an enzymatic digestion of a DNA fragment 
containing the polymorphic site, previously amplified by PCR. If the individual 
analyzed carries a  homozygous genotype for a SNP that eliminates a restriction 
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site, the enzyme will not be able to cut and gel electrophoresis will show a 
single band of the same size of the amplified fragment. On the contrary, if the 
individual is homozygous for an allele that maintains a cleavage site, two bands 
will be observed on the gel indicating that the enzyme has cut the amplified 
fragment. In heterozygous individual in whom both alleles are present, three 
bands can be observed on the gel, one of the same size of the amplified 
fragment and two of smaller sizes for the digested fragments (Figure 6). 
 
Figure 6. Possibile RFLP data. 
 
The choice of the primers to amplify the regions containing the different 
polymorphisms, should be performed so that the restriction site is not exactly in 
the middle of the amplicon in order to obtain two fragments sufficiently 
different to be discriminated  as two distinct bands on agarose gel. 
There are several parameters potentially influencing the restriction 
enzyme reaction: (1) DNA substrate (quantity, quality), (2) optimum reaction 
buffer (pH, salts, cofactors), (3) optimum reaction temperature, (4) enzyme 
(quantity, alterations to the specificity of cut), (5) response time, (6) volume of 
reaction. 
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3.6     NGAL/P121S, NGAL/T124M POLYMORPHISM ANALYSIS BY 
PCR-RFLP 
 
To perform the analysis of polymorphisms of NGAL, the design of 
primers (synthesized by MWG http://www.mwg-biotech.com/) was performed by 
use of the program Primer3 Output, referring to the sequences in the public 
database GenBank..  
For each gene the SNP was identified on the nucleotide sequence and 
has been identified the most suitable pair of primers. 
The two SNPs to be analyzed are located upstream of the 5'; they are 
separated by few basis,so the primers were chosen to amplify a long fragment 
which contains both polymorphisms (Figure 7). 
 
 
 
 
Figure  7. Long fragment to be amplified with primers highlighted (in blue) and SNPs 
(in red). 
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The primers were tested using Oligo primer toolkit. The specificity of 
the sequence was controlled at http://www.ncbi.nlm.nih.gov:80/blast/Blast.cgi.  
To determine the optimum annealing temperature we used a Gradient 
PCR. All samples were amplified with a Eppendorf Mastercycler Gradient. 
The primer pairs used for each gene and their characteristics are shown 
in Table 7. 
 
Table 7. Schematic summary of the primers used, the Tm and the size of the 
amplicon. 
 
Gene Genbank Primer sequences (5’ → 3’) Tm (°C) Amplicon 
size 
NGAL Pro121Ser 
U: ccctcccaaggaaaaagaag 
L: ggttctccctgtgaccaaga  
60.04 
60.09 
563 bp 
NGAL  Thr124Met 
U: ccctcccaaggaaaaagaag 
L: ggttctccctgtgaccaaga 
60.04 
60.09 
563 bp 
 
The amplifications were performed in reaction volumes of 25 μL using 
the enzyme AmpliTaq Gold DNA polymerase (Applied Biosystems).  
The reaction mixtures are described in detail below: 
− 2.5 mL 10x Buffer to a final concentration of 1X;  
− 0.2 mM dNTPs;  
− 6.25 pmol of each primer;  
− 0.5 U AmpliTaq Gold DNA Polymerase;  
− 3.0 mM MgCl2;  
− 150 ng of genomic DNA;  
− DNase RNase free distilled water to a final volume of 25 mL. 
 
The thermal profile consisted of the following steps:  
 
1. Initial denaturation of the templates at 94°C for 7 minutes.  
2. Denaturation of the strands at 94°C for 30 seconds.  
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3. Annealing of the primers at 62°C for 30 seconds.  
4. Extension at 72°C for 30 seconds. 
Phases 2, 3 and 4 were repeated for a total of 35 cycles  
5. Final extension at 72°C for 10 minutes.  
6. Block of the reaction at 4°C. 
 
Aliquots of 4.5 μL of the PCR products were loaded on 1.5% agarose gel 
to estimate the amount of DNA present and its quality (Figure 8).  
 
 
 
Figure 8. Agarose gel electrophoresis of amplified NGAL fragment. 
 
Then 5 μL of the amplicons were subjected to digestion with the 
appropriate restriction enzyme to identify the genotype. Restriction enzymes 
were chosen with the NEBcutter web-based software tool 
(http://tools.neb.com/NEBcutter2/index.php) for identifying endonucleases 
applicable for the genotyping of the 2 SNPs. 
Eco 91I (Bste II) (Fermentas Life Sciences) cloned from Escherichia coli 
RFL91 was used for NGAL Pro121Ser polymorphism, this enzyme works 
under optimal conditions at 37°C and is inactivated at 65°C. 
NGAL Thr124Met polymorphism was analyzed using the Vsp I (Ase I) 
(Fermentas Life Sciences) cloned from Vibrio species, which has an optimum 
temperature of 37°C and is inactivated at 65°C. 
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The restriction sites of enzymes and the dimension of the fragment 
generated are reported in the Table 8. 
 
Table 8. Schematic summary of the enzymes used, with the corresponding restriction  
sites and fragments generated.  
 
Gene SNP Amplicon 
(bp) 
Restriction 
enzymes 
Restriction sites Fragment 
size (bp) 
NGAL C/T 563 Bste II 
5’…G G T N A C C...3’ 
3’ …C C A N T G G... 5’ 
T 563 
C 284 -279 
NGAL C/T 563 Ase I 
5’ ...A T T A A T... 3  ´
3’ ... T A A T T A... 5’ 
T 563 
C 294 -269 
 
 
The protocols of digestion were as follows:  
− 5 µL PCR reaction misture  
− 1 µL 10 X Buffer 0  
− 1 µL Eco91I  
− 8 μL Nucleare-free water to a final volume of 15 μl 
 
The reaction was made to be 37°C for 3 hours, followed by 20 minutes 
at 65°C to inactivate the enzyme. 
 
3.7     STATISTICAL ANALYSIS 
 
Descriptive data are presented as mean ± SD or number and percentage, 
and biomarker levels are expressed as median and range. The normal 
distribution of each continuous variable was verified by the Kolmogorov-
Smirnov test. 
Descriptive analysis was performed by routine tests. The data 
distribution was represented with Box and Whisker plots and was compared 
using nonparametric tests (Mann Whitney and Kruskal Wallis test). The level 
of significance in all cases was set at p <0.05.  
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Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, 
NC). 
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4.     RESULTS AND DISCUSSION 
 
4.1      VLBW INFANTS 
In the present study 55 infants were evaluated. Most of them (44/55, 
80%) showed an increased eGFR during the first 3 weeks of life (NRF group), 
which is consistent with results reported by Gallini and Miall [Gallini et al. 
2000; Miall et al. 1999]. The remaining 11 infants (20%) demonstrated stable 
or progressively deteriorating renal function (IRF group).  
Both uNGAL levels and normalized uNGAL/uCreat values at birth were 
significantly higher in the IRF group than in the NRF group. 
In our population of VLBW infants, we found a positive correlation of 
uNGAL values at birth with differences in sCreat and eGFR values from birth 
to day 21, but no correlation was found between uNGAL values at birth and 
sCreat and eGFR at day 7. 
The uNGAL values at birth were positively correlated with differences 
in sCreat (r=0.51, p=0.0012) and eGFR values (r=-0.38, p=0.0190) from birth 
to day 21 (Figure 9). 
 
 
Figure 9.  Spearman correlation plot between uNGAL at birth and differences in 
sCreat from birth to day 21 (r=0.51, p=0.0012). 
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The sensitivity and the specificity of uNGAL as an early marker of 
impaired renal function were compared using four different cut-off values: 50, 
100, 150, or 200 ng/ml (Figure 10). 
AUC was greater than 0.75 for cut-off values 100, 150, and 200 ng/ml. 
ROC analysis revealed that the cut-off value of 100 ng/ml was able to identify 
neonates with impaired renal function during the first weeks of life, with a 
specificity of 67% and a sensitivity of 100%. 
   
    
                            
 
Figure 10. The sensitivity and specificity of uNGAL as a predictor of renal function 
in first 3 week of life.  
 
 
In conclusion, renal function in VLBW infants was associated with 
urinary NGAL levels in the first day of life. It is feasible that ischemic damage 
of the renal parenchyma leads to a diminished nephrogenesis in these infants, 
but there is also possibility that other factors (maternal, environmental, or 
genetic) might affect renal development and increase the risk of comorbidities 
in premature infants.  
Thus, using the cut-off value of 100 ng/ml, uNGAL may be useful as a 
biomarker to identify VLBW neonates with impaired renal function during the 
first 3 weeks of life. 
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4.2      PREECLAMPSIA 
In our study we compared urinary NGAL levels between pregnant 
women affected by PE and women with uncomplicated pregnancies. A positive 
correlation was found between urinary NGAL and 24 hours proteinuria within 
the PE group (Figure 11).  
 
 
Figure 11.  Correlation between urinary NGAL and 24 h proteinuria. 
 
Urinary NGAL concentrations showed a direct correlation with the 
entity of urinary protein loss. In preeclamptic women urinary excretion of total 
protein was higher than in those with uncomplicated pregnancy. This increase 
is secondary to additional impairment of proximal tubular function, together 
with alteration of the molecular size constraints and of electrostatic properties 
of the glomerular filter. According to our data, most of the fraction of NGAL 
produced at a systemic level is lost through damaged glomerulus, as for other 
plasmatic proteins. Furthermore a quantity of urinary NGAL can be attributed 
to a response of renal tubules to the condition of stress linked to the transit of 
blood proteins. Indeed, proteinuria itself constitutes a factor of renal damage 
caused by the toxicity of the plasmatic proteins on tubular cells, particularly 
proximal ones. On one hand there can be a passive loss of NGAL for an 
inadequate proximal tubular resorption, on the other hand there can be an active 
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production of NGAL by tubular damaged cells as a compensatory mechanism 
with defensive intent. For all these reasons urinary NGAL can be in some way 
an expression of renal suffering. 
Our study has several strengths. We evaluated for the first time and with 
a prospective study NGAL in pregnancies complicated by PE (Figure 12). 
 
 
Figure 12.  NGAL distribution as regard to severity of PE. 
 
The detection of higher uNGAL values in case of severe PE, even in 
absence of statistical significance, confirms that these women suffer from an 
initial renal damage. 
However, a panel of selected proteins rather than a single biomarker 
might provide the elusive panel for an early and rapid detection of kidney 
damage. 
 
 
4.3      KIDNEY TRANSPLANTATION 
A positive correlation was found between the trend of uNGAL before 
transplantation (T0) and 30 days after the transplantation (T5), as shown in 
Figure 13. 
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 Moreover, we observed that patients whose NGAL urine levels were 
elevated before transplantation, also showed higher levels at 30 days. 
 
 
Figure 13. Positive correlation between uNGAL T0 and uNGAL T5. 
  
Delayed graft function (DGF) is believed to adversely impact both short- 
and long-term renal allograft function. However, there is not a definition unique 
to this condition. Although a standardized definition for DGF is lacking, it is 
most commonly defined as the need for dialysis within the first week after 
transplant.  
In our patients population, 17 of them experienced DGF, and they also 
displayed a significant increase in NGAL urine levels compared to those with 
immediate recovery of their graft function (early graft function, EGF) (Figure 
14). 
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Figure 14.  Correlation between uNGAL and DGF (p value<0.05). 
 
In renal transplantation NGAL seems to play a promising role as a marker of 
graft functional recovery. NGAL showed a significant predictivity on DGF. 
 The curve of reduction of uNGAL appeared to be very different between 
patients with or without DGF. In particular, even similar pre-transplant 
NGAL levels can result in different post-transplant behaviors in terms of 
NGAL values and clinical outcomes.  
 In the patients with immediate recovery of their graft function (EGF), 
NGAL levels decreased immediately and rapidly until values below 200 
ng/ml within fifteen days post-transplant, generally showing the most 
prominent reduction in the first week and then reaching a plateau.  
 In contrast, patients with DGF showed persistently elevated levels of 
NGAL in the first week post-transplant, followed by a rapid drop in 
coincidence with the time of DGF resolution, as documented by the 
* 
* 
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marked difference in NGAL levels determined at day 7 and at day 15 
following renal transplant. However, in spite of this reduction, NGAL 
levels remain high (> 200ng/ml) in the first 1 month, possibly indicating 
a worse clinical outcome still being resolved. 
 Based on this results, it appears that the most relevant parameter is the 
relative decrease of NGAL with respect to the previous determination, 
rather than the absolute value of NGAL.   
 
Several studies have demonstrated that delayed graft function (DGF) of 
the kidney results in increased length of hospital stay, increased incidence of 
acute rejection and inferior long-term graft survival following kidney 
transplantation. Hence a diagnostic test that identifies DGF reliably and early 
would allow us a better management of transplant patients in both short- and 
long-term.  
Our results indicate the ability of NGAL to predict the delay in 
functional recovery of the graft. 
 
4.4      DIABETIC NEPHROPATHY 
As Figure 15 shows, systolic blood pressure at the first month (M1) 
decreased with increasing levels of uNGAL. The patients with uNGAL <25 
ng/ml had significantly higher levels of systolic blood pressure compared with 
the patients with uNGAL >50 ng/ml ( p<0.005). 
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Figure 15.  Systolic blood pressure at the first month (M1)  in the three groups of 
diabetic patients (* denotes p< 0.05). 
 
 
Similarly, we observed that the patients with uNGAL < 25 ng/ml 
showed higher diastolic blood pressure at M1 levels compared to those with 
uNGAL > 50 ng/ml (Figure  16).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.  Diastolyc blood pressure at the first month (M1)  in the three groups of 
diabetic patients (* denotes p< 0.05). 
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Diastolic blood pressure at M1 tended to be higher in patients with 
uNGAL values between 25 and 50 than in patients with uNGAL > 50 ng/ml, 
although not significantly.  
A significant association was also found between the trend of the 
diastolic blood pressure after 10 months (M10) and uNGAL (Figure 17).  
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  Diastolyc blood pressure at the tenth month (M10) in the three groups of 
diabetic patients (* denotes p< 0.05). 
 
 
Patients with uNGAL < 25 ng/ml revealed higher levels compared to 
patients with those with uNGAL > 50 ng/ml. Also in this case the values of the 
diastolic blood pressure after 10 months (M10) were increased (not 
significantly) in the group of patients with uNGAL values between 25 ng/ml 
and 50 ng/ml in comparison to the ones with uNGAL > 50 ng / ml.  
 
Recent literature proved evidence of a correlation between the changes 
in NGAL levels and the presence of microalbuminuria. However, our data 
lacked finding such a correlation.  
The parameters that we considered in the diabetic population did not 
show significant associations of NGAL with epidemiological data or diabetes 
complications. In particular uNGAL was not correlated with sex, age, body 
 
 
67
68
69
70
71
72
73
74
75
76
77
<25 25.1-50 >50
D
ia
st
o
lic
 B
P
 M
1
0
 (
m
m
H
g)
mg/dl mg/dlmg/dl
*
 54 
weight, BMI, HbA1c, microalbuminuria, GFR. The only parameter displaying a 
significant association with uNGAL was blood, although this correlation was 
different from the expected, as it was a negative correlation: this means that 
increased values of blood pressure correlated with decreased uNGAL levels. 
Patients with different blood pressure did not differ in terms of epidemiological 
features, so they were statistically comparable. 
In this framework, the role of NGAL is of difficult interpretation since it 
is commonly accepted as a marker of acute kidney injury. However, there are 
other effects of NGAL that are probably related to "chronic" processes 
occurring over time. In particular NGAL is known as an iron carrier and as a 
factor controlling cell transdifferentiation, especially in the kidney. The rise in 
NGAL levels in diabetic patients might be considered in this perspective. 
Higher values of NGAL may be explained  by an increased need for NGAL as 
a antiseptic factor, or they by the expression of a more active basic metabolism 
in kidney cells with superior iron-dependent gene activation. 
Finally, it is known that kidney in type 1 diabetes undergoes early to 
phenomena of hyperfiltration and hypertrophy which result in an increase in 
kidney volume and in an elevated stimulus  to neocytogenesis, and increase of 
nephron numbers and size. Elevated NGAL values in diabetic patients may be 
the expression of a mechanism of both defense and support to the anabolic 
phenomena related to type 1 diabetes. 
Another data not easy to interpret is the meaning of the low levels of 
NGAL in subjects with high blood pressure. This point may be somehow the 
expression of a lower protective capacity and a less effective response of the 
kidney to the need to hyperfiltration and hypertrophy of the typical type 1 
diabetes in the subjects with decreased NGAL levels.  
 
We have also investigated the existence of alternative forms of NGAL 
protein through a qualitative and quantitative analysis of NGAL gene 
polymorphisms. 
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A total of 80 patients with diabetes mellitus type I were genotyped for 2 
polymorphisms of NGAL gene. 
As reported in Table 9, these two SNPs have been identified and selected 
from the SNPs database within National Center for Biotechnology Information 
(NCBI) website (http://www.ncbi.nlm.nih.gov/snp).  
 
Table 9. Characteristics of two SNPs.  
 
  
mRNA 
 
Protein 
Chromosome Function Position Allele change Position Residue change 
Rs2232627 9 missense 434 CCT=>TCT 121 P[Pro]=>S[Ser] 
Rs79993583 9 missense 444 ACG=>ATG 124 T[Thr]=>M[Met] 
 
 
The two polymorphisms are missense SNPs. For the SNP Rs2232627 
(Pro121Ser), if the position 434 of NGAL gene contains a base C, the amino 
acid at position 121 of the protein will be a Proline, while if the base is a T, the 
amino acid will be a Serine. In case of the SNP Rs79993583 (Thr124Me), if the 
position 444 of NGAL gene contains a base C, the amino acid at position 124 
of the protein will be a Threonine, while if the base is a T, the amino acid will 
be a Methionine.  
The frequencies for these polymorphisms are partially known and they 
are available at http://www.ncbi.nlm.nih.gov/snp. 
For the SNP Rs2232627 (Pro121Ser), the genotype distributions were as 
follows: the homozygous CC is 0.990, the heterozygous CT is 0.010, and the 
homozygous TT is unknown; the allele frequencies were 0.995 for the wild 
type allele C and 0.005 for the mutant allele T (Table 10).  
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Table 10. Genotype distributions and allele frequencies for the SNP Rs2232627 
(Pro121Ser) of NGAL gene.  
 
SNP Rs2232627 (Pro121Ser) 
 
 
     
For the SNP Rs79993583 (Thr124Me), the genotype distributions were 
as follows: the homozygous CC is 0.978, the heterozygous CT is 0.022, and the 
homozygous TT is unknown; the allele frequencies were 0.989 for the wild 
type allele C and 0.011 for the mutant allele T (Table 11).  
 
Table 11. Genotype distributions and allele frequencies for the Rs79993583 
(Thr124Me), of NGAL gene.  
 
Rs79993583 (Thr124Me) 
 
 
     
For both polymorphisms, genotype analysis was carried out by RFLP. 
The PCR products were digested simultaneously with the restriction enzymes 
BSTE II and ASE I. To identify the genotype of each patient all digestion 
products were separated on an agarose gel at 2.5% . The results are based on 
the pattern of the bands generated by the digested fragments (Figure 18). 
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Figure 18. Migration of the PCR-RFLP products on agarose gel. 
 
If a subject is homozygous for an allele that maintains a cleavage site, 
two bands will be observed on the gel, indicating that the enzyme has cut. In 
the samples digested with BSTE II it is possible to observe the presence of 2 
bands which signify that the enzyme has recognized the nucleotide sequence to 
be cut (when the base C is present). In the figure, the two bands are not evident 
because they have similar size. If the individual is homozygous for a SNP that 
eliminates a restriction site, the enzyme will not be able to cut and a single band 
of the same size of the amplified fragment will be observed on the gel. In the 
samples digested with ASEI there is only one fragment of 563 bp indicating the 
presence of the base T. For the SNP 121 it is more likely to find the C allele 
compared to T. For the SNP 124 it is more likely to find the C allele compared 
to T. The results obtained are compatible with the frequencies reported in the 
database http://www.ncbi.nlm.nih.gov/snp. 
 We did not find evidence of any significant influence of NGAL genetic 
variants on type 1 diabetes. Our data on SNPs mirror what is already known 
form existing literature. 
 
 
 
298 bp 
234 bp 
692 bp 
501 bp 
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5.      CONCLUSIONS 
 
The behavior of NGAL is quite complex because its performance as a 
predictive biomarker is strictly related to the type disease. 
 
In conclusion, some foremost points emerging from this study are the 
following:   
 
 In acute renal pathology, urinary NGAL confirms to be a valuable 
predictive marker of the progress and status of acute injury. Our 
findings on NGAL efficacy as a marker of DGF in renal 
transplant, of the acute phase of preeclampsia, or as an index in 
worse renal function in VLBW infants.   
 
 In clinical conditions other than acute kidney injury, such as in 
type 1 diabetes, NGAL behavior does not appear to be only 
related to the slow progression of renal damage (i.e. developing 
diabetic nephropathy), but more closely associated with the state 
of the disease, due to functional and microstructural changes 
typical of the diabetic kidney. 
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